Fisetin Senolytic Extended Mouse Lifespan—Human Proof Still Missing
Fisetin, a plant flavonoid, emerged as the most potent senolytic among ten compounds in a widely cited 2018 EBioMedicine study. In aged mice, treatment late in life reduced senescence markers, eased age-related pathology and extended both median and maximum lifespan. The catch is that this is mouse and lab evidence, not a completed human longevity trial. This article explains what the researchers found, what the dosing context really means, and who should pay attention as human studies develop.
The First Humans to Take Dasatinib + Quercetin: What a 14-Patient IPF Pilot Did (and Didn't) Show
In 2019, researchers reported the first-ever human use of the senolytic combination dasatinib plus quercetin, in 14 patients with idiopathic pulmonary fibrosis. After three weeks of intermittent dosing, participants showed meaningful gains in 6-minute walk distance, gait speed and chair-stand time, even though lung function itself did not change. The pilot also logged one serious adverse event and frequent respiratory, skin and GI complaints. But this was an open-label, uncontrolled study of a cancer drug paired with a pharmacologic-dose flavonoid, not a supplement protocol. Here's what the trial actually tested, what it found, and how to read it critically.